EFTR
eFFECTOR Therapeutics, Inc.
Set alert
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- 0.0002
- Prev close
- 0.0002
- Mkt cap
- 940
- Vol
- 331
- Avg vol
- 1.93K
- EPS
- -12.78
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0002
- High
- 0.0002
- Forward P/E
- -0.02
- Beta
- 0.62
- Short ratio
- 0.97
- Inst. own
- 23.45%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Dec 23, 2024
- 50-d avg
- 0.697539
- 200-d avg
- 7.74
- 1y target
- 10.00
Key statistics
- Market cap
- 195.23K
- Enterprise value
- -4.95M
- Trailing P/E
- 0.00
- Forward P/E
- -0.02
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.20
- EPS (TTM)
- -12.57
- Beta
- 0.62
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -17.67M
- Total cash
- 25.38M
- Total debt
- 20.25M
- Return on equity
- 0.00%
- Shares outstanding
- 4.70M
- Short % of float
- 1.97%
- 50-day average
- 0.697539
- 200-day average
- 7.74
Analyst view
Consensus: strong buy
Next earnings
Dec 23, 2024
Expected Dec 23, 2024. Consensus EPS estimate -2.02.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 23, 2024 | Sep 1, 2024 | 0.00 | — | — | — |
| Oct 1, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -2.17 | -2.16 | +0.01 | +0.46% |
| Mar 25, 2024 | Dec 1, 2023 | -2.73 | -3.42 | -0.69 | -25.27% |
| Nov 13, 2023 | Sep 1, 2023 | -3.25 | -3.25 | 0.00 | 0.00% |
| Aug 8, 2023 | Jun 1, 2023 | -4.75 | -4.25 | +0.50 | +10.53% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 23, 2023 | HC Wainwright & Co. | init | — | Buy |
| May 25, 2023 | Stifel | up | Hold | Buy |
| May 9, 2023 | Credit Suisse | main | — | Outperform |
| Mar 8, 2023 | Credit Suisse | main | — | Outperform |
| Jan 8, 2023 | JMP Securities | main | — | Market Outperform |
| Jan 5, 2023 | Credit Suisse | main | — | Outperform |
About eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E; and collaboration agreement with the Dana-Farber Cancer Institute on a Phase 2 clinical trial, evaluating Zotatifin as combination treatment in ER+ endometrial cancer and in low grade serous ovarian cancer. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- effector.com
News
- Comparing eFFECTOR Therapeutics (NASDAQ:EFTR) and Orgenesis (NASDAQ:ORGS)
- eFFECTOR Therapeutics (NASDAQ:EFTR) & NexImmune (NASDAQ:NEXI) Critical Contrast
- BioGene Therapeutics Announces Appointment of Dr. Brian Gallagher, Jr. to Corporate Advisory Board
- 3 Publicly Traded Companies Filing for Bankruptcy as July Kicks Off
- eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq
- eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
- EFTR Stock Earnings: eFFECTOR Therapeutics Meets EPS for Q1 2024
- eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- eFFECTOR Therapeutics to Participate in Upcoming Investor Conference
- eFFECTOR Therapeutics (EFTR) Plunges 82% as NSCLC Study Fails
Your note
Sign in to keep a note on EFTR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BHATT ELIZABETH | Director | Conversion of Exercise of derivative security | Aug 24, 2021 | 0 |
| BYRNES MICHAEL | Chief Financial Officer | Stock Award(Grant) | May 14, 2024 | 3,117 |
| EHRLICH CHRISTOPHER B | Director | Purchase | Oct 3, 2022 | 178,415 |
| GALLAGHER BRIAN M JR. | Director | Purchase | Jun 22, 2022 | 30,000 |
| PRESIDIO MANAGEMENT GROUP X L L C | Beneficial Owner of more than 10% of a Class of Security | Sale | Aug 2, 2022 | 0 |
| ROOT JONATHAN D | Director and Beneficial Owner of more than 10% of a Class of Security | Sale | Dec 1, 2021 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SR One Capital Management, LP | 11.05% | 6,822,114 | 5.66M | Jun 29, 2023 |
| Carlyle Group Inc. | 7.81% | 4,822,114 | 4.00M | Jun 29, 2023 |
| Column Group LLC | 6.98% | 4,309,329 | 3.58M | Jun 29, 2023 |
| Sectoral Asset Management, Inc. | 3.86% | 2,382,644 | 1.98M | Jun 29, 2023 |
| Parallel Advisors, LLC | 2.74% | 1,693,559 | 1.41M | Jun 29, 2023 |
| Blackstone Inc | 2.12% | 1,308,587 | 1.09M | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.49% | 300,033 | 249.09K | Jun 29, 2023 |
| Vanguard Extended Market Index Fund | 0.15% | 94,449 | 78.41K | Jun 29, 2023 |
| Fidelity Extended Market Index Fund | 0.09% | 55,532 | 51.64K | May 30, 2023 |
| Fidelity NASDAQ Composite Index Fund | 0.04% | 24,005 | 22.32K | May 30, 2023 |
| Fidelity Series Total Market Index Fund | 0.02% | 10,545 | 9.81K | May 30, 2023 |
| Fidelity Total Market Index Fund | 0.02% | 9,490 | 8.82K | May 30, 2023 |